Last reviewed · How we verify
NCT02443584: PGX-AMG
Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis
NA trial testing pharmacogenetic testing in Major Depressive Disorder in 84 participants. Completed in 1 April 2017.
1 April 2017
Quick facts
| Lead sponsor | Avera McKennan Hospital & University Health Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 84 |
| Start date | 1 February 2015 |
| Primary completion | 1 April 2017 |
| Estimated completion | 1 April 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- pharmacogenetic testing
Conditions studied
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Avera McKennan Hospital & University Health Center
Who can join
18 and older, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major Depressive Disorder (MDD) or Depressive Disorder Not Otherwise Specified (DDNOS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02443584
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Disorder
Currently open trials in the same condition.
- NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
- NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
- NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting
Other Avera McKennan Hospital & University Health Center trials
Trials by the same sponsor.
- NCT05308784 — A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ · unknown
- NCT05142033 — Avera Cancer Sequencing and Analytics Protocol (ASAP) · recruiting
- NCT03494621 — Infant Care Practices Study · NA · completed
- NCT03345277 — Continuous Temperature Measurement for Syndromic Surveillance · withdrawn
- NCT03154281 — Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02443584 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Avera McKennan Hospital & University Health Center
- Last refreshed: 3 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02443584.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing